Over the last decade there has been growing interest in the role of Vascular Endothelial Growth Factor (VEGF) in the pathogenesis of ILD, with the development of nintedanib for the treatment of IPF, a novel triple tyrosine kinase inhibitor of VEGF, fibroblast derived growth factor (FGF) and platelet derived growth factor (PDGF) receptors [2]. This evidence concerns the gene VEGFA and interstitial lung disease.